144 related articles for article (PubMed ID: 28849031)
21. Canstatin suppresses isoproterenol-induced cardiac hypertrophy through inhibition of calcineurin/nuclear factor of activated T-cells pathway in rats.
Sugiyama A; Okada M; Yamawaki H
Eur J Pharmacol; 2020 Mar; 871():172849. PubMed ID: 31843516
[TBL] [Abstract][Full Text] [Related]
22. Betulinic Acid Improves Cardiac-Renal Dysfunction Caused by Hypertrophy through Calcineurin-NFATc3 Signaling.
Hong MH; Na SW; Jang YJ; Yoon JJ; Lee YJ; Lee HS; Kim HY; Kang DG
Nutrients; 2021 Sep; 13(10):. PubMed ID: 34684485
[TBL] [Abstract][Full Text] [Related]
23. Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides.
Tokudome T; Horio T; Kishimoto I; Soeki T; Mori K; Kawano Y; Kohno M; Garbers DL; Nakao K; Kangawa K
Circulation; 2005 Jun; 111(23):3095-104. PubMed ID: 15939815
[TBL] [Abstract][Full Text] [Related]
24. Cardiomyocyte-specific overexpression of syndecan-4 in mice results in activation of calcineurin-NFAT signalling and exacerbated cardiac hypertrophy.
Lunde IG; Aronsen JM; Melleby AO; Strand ME; Skogestad J; Bendiksen BA; Ahmed MS; Sjaastad I; Attramadal H; Carlson CR; Christensen G
Mol Biol Rep; 2022 Dec; 49(12):11795-11809. PubMed ID: 36205855
[TBL] [Abstract][Full Text] [Related]
25. Baicalein protects against cardiac hypertrophy through blocking MEK-ERK1/2 signaling.
Zong J; Zhang DP; Zhou H; Bian ZY; Deng W; Dai J; Yuan Y; Gan HW; Guo HP; Tang QZ
J Cell Biochem; 2013 May; 114(5):1058-65. PubMed ID: 23225340
[TBL] [Abstract][Full Text] [Related]
26. The Ca(v)3.2 T-type Ca(2+) channel is required for pressure overload-induced cardiac hypertrophy in mice.
Chiang CS; Huang CH; Chieng H; Chang YT; Chang D; Chen JJ; Chen YC; Chen YH; Shin HS; Campbell KP; Chen CC
Circ Res; 2009 Feb; 104(4):522-30. PubMed ID: 19122177
[TBL] [Abstract][Full Text] [Related]
27. Cucurbitacin B Protects Against Pressure Overload Induced Cardiac Hypertrophy.
Xiao Y; Yang Z; Wu QQ; Jiang XH; Yuan Y; Chang W; Bian ZY; Zhu JX; Tang QZ
J Cell Biochem; 2017 Nov; 118(11):3899-3910. PubMed ID: 28390176
[TBL] [Abstract][Full Text] [Related]
28. Astragaloside IV protects against the pathological cardiac hypertrophy in mice.
Liu ZH; Liu HB; Wang J
Biomed Pharmacother; 2018 Jan; 97():1468-1478. PubMed ID: 29793309
[TBL] [Abstract][Full Text] [Related]
29. Cordycepin ameliorates cardiac hypertrophy via activating the AMPKα pathway.
Wang HB; Duan MX; Xu M; Huang SH; Yang J; Yang J; Liu LB; Huang R; Wan CX; Ma ZG; Wu QQ; Tang QZ
J Cell Mol Med; 2019 Aug; 23(8):5715-5727. PubMed ID: 31225721
[TBL] [Abstract][Full Text] [Related]
30. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-328 as a regulator of cardiac hypertrophy.
Li C; Li X; Gao X; Zhang R; Zhang Y; Liang H; Xu C; Du W; Zhang Y; Liu X; Ma N; Xu Z; Wang L; Chen X; Lu Y; Ju J; Yang B; Shan H
Int J Cardiol; 2014 May; 173(2):268-76. PubMed ID: 24631114
[TBL] [Abstract][Full Text] [Related]
32. Stem cell antigen 1 protects against cardiac hypertrophy and fibrosis after pressure overload.
Zhou H; Bian ZY; Zong J; Deng W; Yan L; Shen DF; Guo H; Dai J; Yuan Y; Zhang R; Lin YF; Hu X; Li H; Tang QZ
Hypertension; 2012 Sep; 60(3):802-9. PubMed ID: 22851736
[TBL] [Abstract][Full Text] [Related]
33. Sumoylation-independent activation of Calcineurin-NFAT-signaling via SUMO2 mediates cardiomyocyte hypertrophy.
Bernt A; Rangrez AY; Eden M; Jungmann A; Katz S; Rohr C; Müller OJ; Katus HA; Sossalla ST; Williams T; Ritter O; Frank D; Frey N
Sci Rep; 2016 Oct; 6():35758. PubMed ID: 27767176
[TBL] [Abstract][Full Text] [Related]
34. Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension.
Shimoyama M; Hayashi D; Zou Y; Takimoto E; Mizukami M; Monzen K; Kudoh S; Hiroi Y; Yazaki Y; Nagai R; Komuro I
Circulation; 2000 Oct; 102(16):1996-2004. PubMed ID: 11034951
[TBL] [Abstract][Full Text] [Related]
35. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
[TBL] [Abstract][Full Text] [Related]
36. Tropisetron inhibits high glucose-induced calcineurin/NFAT hypertrophic pathway in H9c2 myocardial cells.
Asadi F; Razmi A; Dehpour AR; Shafiei M
J Pharm Pharmacol; 2016 Apr; 68(4):485-93. PubMed ID: 26945895
[TBL] [Abstract][Full Text] [Related]
37. Oleanolic acid alleviated pressure overload-induced cardiac remodeling.
Liao HH; Zhang N; Feng H; Zhang N; Ma ZG; Yang Z; Yuan Y; Bian ZY; Tang QZ
Mol Cell Biochem; 2015 Nov; 409(1-2):145-54. PubMed ID: 26215454
[TBL] [Abstract][Full Text] [Related]
38. Olmesartan attenuates cardiac hypertrophy and improves cardiac diastolic function in spontaneously hypertensive rats through inhibition of calcineurin pathway.
Fu M; Zhou J; Xu J; Zhu H; Liao J; Cui X; Sun A; Fu M; Zou Y; Hu K; Ge J
J Cardiovasc Pharmacol; 2014 Mar; 63(3):218-26. PubMed ID: 24603116
[TBL] [Abstract][Full Text] [Related]
39. Sanguinarine protects against pressure overload‑induced cardiac remodeling via inhibition of nuclear factor-κB activation.
Deng W; Fang Y; Liu Y; Zhou H; Cheng Z; Zhang Y; Sun D; He M; Lin Y; Zhang R; Zhang J; Li W; Tang Q
Mol Med Rep; 2014 Jul; 10(1):211-6. PubMed ID: 24804701
[TBL] [Abstract][Full Text] [Related]
40. Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2+/calmodulin-dependent protein kinase II signaling.
Bisserier M; Berthouze-Duquesnes M; Breckler M; Tortosa F; Fazal L; de Régibus A; Laurent AC; Varin A; Lucas A; Branchereau M; Marck P; Schickel JN; Deloménie C; Cazorla O; Soulas-Sprauel P; Crozatier B; Morel E; Heymes C; Lezoualc'h F
Circulation; 2015 Jan; 131(4):390-400; discussion 400. PubMed ID: 25369805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
